Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16955639 | 0.83 | KAT6A (0.41) | KAT6ATSHRCES2CES1CYP11B1 | |
| SCHEMBL29454770 | 0.81 | ALDH1A1 (0.54) | KAT6ATSHRCES2CES1CYP11B1 | |
| SCHEMBL31410035 | 0.81 | HPGD (0.53) | TSHRCES2CES1NOTUMALDH1A1 | |
| SCHEMBL401838 | 0.81 | TSHR (0.63) | KAT6ATSHRCES2CES1NOTUM | |
| SCHEMBL413285 | 0.81 | ALDH1A1 (0.54) | KAT6ATSHRCES2CES1CYP11B1 | |
| SCHEMBL30462062 | 0.81 | TSHR (0.63) | KAT6ATSHRCES2CES1NOTUM | |
| SCHEMBL9693738 | 0.81 | KAT6A (0.47) | KAT6ATSHRCES2CES1CYP11B1 | |
| Hydrochloric Acid SCHEMBL10557491 | 0.79 | TSHR (0.61) | KAT6ATSHRCES2CES1NOTUM | |
| SCHEMBL29975438 | 0.79 | PBRM1 (0.49) | KAT6ATSHRCES2CES1CYP11B1 | |
| SCHEMBL2175638 | 0.79 | PBRM1 (0.49) | KAT6ATSHRCES2CES1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637461-B2 | Compounds for the activation of AMPK | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | ASTRAZENECA AB (SE) | 2025-09-02 | — | — | US | disclosed |
| EP-4605388-A1 | <SUP2/>? <SUB2/>?3?2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CXCR1 | Astrazeneca AB (SE) | 2025-08-27 | — | — | EP | disclosed |
| CN-120077035-A | As CX32,4, 6-Trisubstituted 1,3, 5-triazines as modulators of CR1 | 阿斯利康(瑞典)有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20250092009-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-03-20 | — | — | US | disclosed |
| CN-119522208-A | Effective methods for modulating NMDA receptor-mediated toxicity | 智基药业有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240383866-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | ASTRAZENECA AB (SE) | 2024-11-21 | — | — | US | disclosed |
| US-20240199558-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | US | disclosed |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20240182468-A1 | COMPOUNDS FOR THE ACTIVATION OF AMPK | PFIZER (US) | 2024-06-06 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-2114906-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009130232-A1 | PYRAZOLO [1, 5 -A] PYRAZINE DERIVATIVES AS ANTAGONISTS OF V1B RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | WO | disclosed |
| EP-2002834-A1 | Aryl and hetaryl amides as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-12-17 | — | — | EP | disclosed |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-23 | — | — | US | disclosed |
| WO-2008092785-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | WO | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-0735142-B1 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICALS CO LTD (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-5717116-A | TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0735142-A2 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182468-A1 | COMPOUNDS FOR THE ACTIVATION OF AMPK | PRKAG1, PRKAG2, PRKAB1 | KAT6A 1282/4885TSHR 3141/4885CES2 3030/4885 |
| US-20240199558-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | CX3CR1, CCR2, CCR5 | KAT6A 4334/4885TSHR 1113/4885CES2 3829/4885 |
| US-20240383866-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | CX3CR1, CCR2, CCR5 | KAT6A 4334/4885TSHR 1113/4885CES2 3829/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | KAT6A 4448/4885TSHR 267/4885CES2 4635/4885 |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | CX3CR1, CCR2, CCR5 | KAT6A 4334/4885TSHR 1113/4885CES2 3829/4885 |
| US-12637461-B2 | Compounds for the activation of AMPK | PRKAG1, PRKAB1, PRKAA1 | KAT6A 690/4885TSHR 794/4885CES2 1535/4885 |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | TAAR1, TAAR5, NPY2R | KAT6A 3668/4885TSHR 38/4885CES2 1102/4885 |
| US-20250092009-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | STING1, CGAS, IRF3 | KAT6A 206/4885TSHR 1608/4885CES2 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.